Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Biganzoli, L.
Right arrow Articles by Piccart, M. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Biganzoli, L.
Right arrow Articles by Piccart, M. J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:207-210, 2004
© 2004 European Society for Medical Oncology

Original Paper

Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG)

Received 8 August 2003; accepted 3 October 2003

Background:

To collect oncologists’ experience and opinion on adjuvant chemotherapy in elderly breast cancer patients.

Materials and methods:

A questionnaire was circulated among the members of the Breast International Group.

Results:

A total of 277 oncologists from 28 countries participated in the survey. Seventy years is the age cut-off commonly used to define a patient as elderly. Biological age and the biological characteristics of the tumor are the most frequently used criteria to propose adjuvant chemotherapy to an elderly patient. Combination therapy with cyclophosphamide, methotrexate and fluorouracil on days 1 and 8 is the most frequently prescribed regimen. Great interest exists in oral chemotherapy.

Conclusion:

There is interest among those who responded to the survey to validate a comprehensive geriatric assessment for use as a predictive instrument of toxicity and/or activity of anticancer therapy and to evaluate the role of a treatment option that is potentially less toxic and possibly as effective as polychemotherapy.

L. Biganzoli1,*, A. Goldhirsch2, C. Straehle3, M. Castiglione-Gertsch4, P. Therasse5, M. Aapro6, A. Minisini7 and M. J Piccart1

1 Jules Bordet Institute, Brussels, Belgium; 2 European Institute of Oncology, Milan, Italy; 3 BIG secretariat, Brussels, Belgium; 4 IBCSG Coordinating Center, Bern, Switzerland; 5 EORTC Data Center, Brussels, Belgium; 6 Multidisciplinary Oncology Institute, Clinique de Genolier, Genolier for the EORTC Task Force Cancer in the Elderly; 7 EORTC-IDBBC, Brussels, Belgium

Key words: adjuvant chemotherapy, breast cancer, elderly, geriatric oncology, survey


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
H. B. Muss, D. A. Berry, C. Cirrincione, D. R. Budman, I. C. Henderson, M. L. Citron, L. Norton, E. P. Winer, and C. A. Hudis
Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience
J. Clin. Oncol., August 20, 2007; 25(24): 3699 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Mustacchi, M. Cazzaniga, P Pronzato, A De Matteis, F Di Costanzo, I Floriani, and On behalf of the NORA Study Group
Breast cancer in elderly women: a different reality? Results from the NORA study
Ann. Onc., June 1, 2007; 18(6): 991 - 996.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Brunello, U. Basso, C. Pogliani, A. Jirillo, C. Ghiotto, H. Koussis, F. Lumachi, M. Iacobone, L. Vamvakas, and S. Monfardini
Adjuvant chemotherapy for elderly patients (>=70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients
Ann. Onc., August 1, 2005; 16(8): 1276 - 1282.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.